Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) ended Thursday session in red amid volatile trading. The shares closed down -0.078 points or 12.37% at $0.552 with 3.27 million shares getting traded. Post opening the session at $0.62, the shares hit an intraday low of $0.55 and an intraday high of $0.67 and the price vacillated in this range throughout the day. The company has a market cap of $56.60 million and the numbers of outstanding shares have been calculated to be 113.74 million shares.
Northwest Biotherapeutics, Inc (NWBO) discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patients own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate, which is under Phase III for prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) ended Thursday session in green amid volatile trading. The shares closed up +1.06 points or 6.81% at $16.62 with 3.23 million shares getting traded. Post opening the session at $15.52, the shares hit an intraday low of $15.15 and an intraday high of $18.00 and the price vacillated in this range throughout the day. The company has a market cap of $732.09 million and the numbers of outstanding shares have been calculated to be 43.28 million shares.
Vanda Pharmaceuticals Inc. (VNDA) on Aug. 25, 2016 announced that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that Roxane Laboratories Inc. (Roxane) infringed U.S. Patent Nos. RE39,198 (the ‘198 Patent) and 8,586,610 (the ‘610 Patent) by submitting to the FDA an ANDA seeking permission to market a generic version of Fanapt® before the expiration of Vanda’s patents.
“We are very pleased that the court found both patents valid, found that Roxane’s ANDA infringes the ‘198 patent and the ‘610 patent, and accordingly issued an injunction barring Roxane from marketing its product until the expiration of the later expiring ‘610 patent on November 2, 2027,” said Mihael H. Polymeropoulos, M.D., Vanda’s President and CEO.